New NIH grant supports Vivasc's work to reverse molecular causes of heart failure

Oct. 20, 2022

Vivasc Therapeutics Inc. has initiated work under a second National Institutes of Health (NIH) phase I STTR research grant, in conjunction with Georgetown University.

BioWorld Science Collaboration Cardiovascular Peptide Grant NIH

Today's news in brief

BioWorld

BioWorld briefs for April 7, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 4, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Another rebound as Sangamo inks $1.4B capsid deal with Lilly

BioWorld

Sangamo Therapeutics Inc. is adding a much-needed $18 million up-front payment in a neurology-focused deal with Eli Lilly and Co. that could bring up to an...

Impact of Trump tariffs on med tech proving difficult to anticipate

BioWorld MedTech

The Trump administration’s declaration of a new round of tariffs did not sit well with trade associations, but the impact of those tariffs may vary somewhat by...